Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2)

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2953-2960

  Hirt, Déborah ^a,b,c   Pruvost, Alain ^d   Ekouévi, Didier K ^c,e   Urien, Saïk ^a,c,f   Arrivé, Elise ^c   Kone, Mamourou ^g   Nerrienet, Eric ^h   Nyati, Mandisa ⁱ   Gray, Glenda ⁱ   Kruy, Leang Sim ^j   Blanche, Stéphane ^k   Dabis, François ^e   Tréluyer, Jean Marc ^a,c,f  

^a Assistance Publique Hôpitaux de Paris ^*  (France)

^b CNRS   (France)

^c INSERM   (France)

^d SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^e Programme PAC CI   (Côte d’Ivoire)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^h INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j Hopital Calmette   (Cambodia)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEWBORN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREGNANT WOMAN; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADULT; ANTIVIRAL AGENTS; DEOXYCYTIDINE; FEMALE; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PHOSPHONIC ACIDS; PHOSPHORYLATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES;

EID: 79956312570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01376-10     Document Type: Article

References (18)

1. Anderson, P. L., T. N. Kakuda, and K. A. Lichtenstein. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-753.
2. Arrive, E., et al. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36:1009-1021.
3. Bazzoli, C., et al. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49:17-45.
4. Blum, M. R., G. E. Chittick, J. A. Begley, and J. Zong. 2007. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47:751-759.
5. Chi, B. H., et al. 2007. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 370:1698-1705. (Pubitemid 350100773)
6. Durand-Gasselin, L., D. Da Silva, H. Benech, A. Pruvost, and J. Grassi. 2007. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 51:2105-2111.
7. Durand-Gasselin, L., et al. 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob. Agents Chemother. 52:2555-2563.
8. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
9. Hirt, D., et al. 2009. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob. Agents Chemother. 53:1067-1073.
10. Kuhn, E., and M. Lavielle. 2005. Maximum likelihood estimation in nonlinear mixed effects models. Comput. Stat. Data Anal. 49:1020-1038.
11. Pruvost, A., et al. 2009. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob. Agents Chemother. 53:1937-1943.
12. Pruvost, A., F. Theodoro, L. Agrofoglio, E. Negredo, and H. Benech. 2008. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. J. Mass Spectrom. 43:224-233. (Pubitemid 351303443)
13. Ramanathan, S., G. Shen, A. Cheng, and B. P. Kearney. 2007. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J. Acquir. Immune Defic. Syndr. 45:274-279.
14. Rousseau, F. S., et al. 2001. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J. Antimicrob. Chemother. 48:507-513. (Pubitemid 33040691)
15. TEmAA ANRS 12109 Study Group. 2010. Maternal and nenonatal nevirapine, tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. AIDS 24:2481-2488.
16. Venhoff, N., B. Setzer, K. Melkaoui, and U. A. Walker. 2007. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. 12:1075-1085.
17. Wang, L. H., et al. 2004. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses 20:1173-1182.
18. Zong, J., et al. 2007. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J. Clin. Pharmacol. 47:877-889.